The Shanghai Waigaoqiao-Hong Kong Biopharmaceutical Innovation Liaison Station was officially inaugurated recently through a hybrid online-offline ceremony, establishing a new platform for deeper integration between the two cities' life sciences sectors.
The launch coincided with the station's first joint promotional event held simultaneously in Shanghai and Hong Kong.
Co-organized by Shanghai Waigaoqiao Group and the Hong Kong Biotechnology Organization, the event also marked the preliminary phase of the 2025 Shanghai-Hong Kong Innovation Awards, which will evaluate cutting-edge biopharma projects through October.
Cheung Kwok-ching, president of the Hong Kong Chamber of Commerce in Shanghai, outlined the initiative's vision: "This awards program will refine our dual-city incubation mechanism, pioneering a 'Hong Kong R&D + Shanghai commercialization' model to create an internationally distinctive innovation platform."
Since signing a cooperation memorandum in October 2024, Waigaoqiao Biopharma and the Hong Kong Biotechnology Organization have expanded collaboration across multiple fronts, including establishing reciprocal liaison offices, co-hosting industry events, facilitating investor dialogues and advancing healthcare data services.
The new liaison station will further synchronize industrial resources and innovation capabilities, attracting high-quality projects to accelerate breakthroughs in biopharma technology and industrial advancement.
Industry leaders anticipate the station will streamline cross-border regulatory coordination, enhance talent exchange programs, develop shared laboratory facilities and expand clinical trial partnerships.
